Understanding CNS Risk Before the First Dose
Dear Kenneth,
Developing therapies that act on the central nervous system requires navigating complex safety, translational, and regulatory considerations. Early nonclinical findings such as seizure signals, CNS exposure, or target-related toxicities, often shape how first-in-human studies are designed and reviewed.
In this webinar, you’ll learn:
- Why CNS drug development carries distinct risk assessment challenges
- How nonclinical pharmacology, toxicology, and PK/PD data inform early decisions
- What regulators look for when evaluating CNS safety before clinical entry
Register now to learn how to translate nonclinical CNS data into confident clinical decisions.
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Allucent or a third party to contact you regarding the content (by phone or email).